Antiviral agents against HBV infection

A compound of Formula (I), or an enantiomer, diastereomer, pharmaceutically accepted salt, or solvate thereof:

• wherein in (I):
• A is selected from the group consisting of SO2 and CO;
• R1 is selected from the group consisting of optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted benzyl, optionally substituted 3-7 membered cycloheteroalkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, and optionally substituted heterocyclic;
• R2 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C3-7 cycloalkyl, and optionally substituted heterocyclic;
• R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
• R4 is selected from the group consisting of hydrogen and optionally substituted C1-6 linear alkyl;
• R5 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C1-6 haloalkyl, OR9, cyano, and N(R9)2;
• R6 and R8 are selected independently at each occurrence from the group consisting of fluoro, C1-3 alkyl, and C1-3 alkoxy;
• R7 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, OR9, cyano, and N(R9)2;
• R9 is independently at each occurrence selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted benzyl, and optionally substituted heterocyclyl;
• wherein a substituted group is substituted with at least one selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, —F, —Cl, —Br, —I, —CN —NO2, —OR41 , —SR14, —N(R14)2, —NR14C(O)R14,—SO2 R14 ,—SO2 OR14 —SO2N(R14)2, —C(O)R14, —C(O)OR14 —C(O)N(R14)2, aryl, heterocyclyl, or heteroaryl, wherein each occurrence of R14 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, and C3-6 cycloalkyl, or two R14 units taken together with the atom(s) to which they are bound form an optionally substituted carbocyclyl or heterocyclyl group, wherein the carbocyclyl or heterocyclyl group has 3 to 7 ring atoms,
• wherein the heteroaryl is selected from the group consisting of diazolyl, imidazolyl, imidazolyl, triazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolinyl, furanyl, thiophenyl, pyrimidinyl, pyridinyl, tetrazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H -purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-(ijpyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, and isoquinolinyl;
• provided that, when A is SO2, then the compound is not selected from any of groups (a) through (c):
• (a) R3 is optionally substituted phenyl and R1or R2, either individually or when taken together, contain a hydroxyl group;
• or
• (b) R3 is optionally substituted phenyl, and N(R1)(R2) is selected from the group consisting of
• or
• (c) R3 is optionally substituted phenyl and N(R1)(R2) is selected from the group consisting of: